IMPLANET’s JAZZ range has been approved by the China Food and Drug Administration. Commercial launch is slated for early in 4Q25.
As part of a distribution partnership signed in 2022, IMPLANET and Sanyou Medical have successfully registered the JAZZ range, dedicated to tape fixation in the treatment of spinal pathologies, on the Chinese market. The JAZZ system can be used with the full range of spinal fixation systems already developed by Sanyou.
Ludovic Lastennet, CEO of IMPLANET, said, “Obtaining the registration certificates for our JAZZ range from the CFDA marks a major new turning point for Implanet, and once again attests to the high clinical value of our JAZZ technology. Penetration of the Chinese market, through our alliance with SanYou Medical, has been at the heart of our strategy since 2022. SanYou Medical’s marketing and commercial strength in China should rapidly provide Implanet with new resources to accelerate its development in one of the world’s most important markets.”
IMPLANET's JAZZ range has been approved by the China Food and Drug Administration. Commercial launch is slated for early in 4Q25.
As part of a distribution partnership signed in 2022, IMPLANET and Sanyou Medical have successfully registered the JAZZ range, dedicated to tape fixation in the treatment of spinal pathologies, on the Chinese...
IMPLANET’s JAZZ range has been approved by the China Food and Drug Administration. Commercial launch is slated for early in 4Q25.
As part of a distribution partnership signed in 2022, IMPLANET and Sanyou Medical have successfully registered the JAZZ range, dedicated to tape fixation in the treatment of spinal pathologies, on the Chinese market. The JAZZ system can be used with the full range of spinal fixation systems already developed by Sanyou.
Ludovic Lastennet, CEO of IMPLANET, said, “Obtaining the registration certificates for our JAZZ range from the CFDA marks a major new turning point for Implanet, and once again attests to the high clinical value of our JAZZ technology. Penetration of the Chinese market, through our alliance with SanYou Medical, has been at the heart of our strategy since 2022. SanYou Medical’s marketing and commercial strength in China should rapidly provide Implanet with new resources to accelerate its development in one of the world’s most important markets.”
Copy to clipboard 
